The previous studies indicate that ACSL3 overexpression was associated with worse clinical outcomes in patients with NSCLC and melanoma (Chen et al., 2016; Padanad et al., 2016); in contrast, high ACSL3 expression predicted a better prognosis in ovarian cancer (Chen et al., 2016). This evidence concerns the gene ACSL3 and melanoma.